retatrutide clinical trial phase retatrutide Availability & Timeline Retatrutide Dosing: Early Clinical Trial

As of March 2026, retatrutide is investigational

M., Killian, L., et al

Recently published four-arm target trial which included 283 998 patients compared effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors and sulfonylureas

GLP-1 receptor agonistsmedications used for type 2 diabetes and weight managementhave elimination times ranging from hours to several weeks after your last dose

The real question: Will either medication achieve the sustained, widespread use needed to address the global obesity epidemic

This review aims to put these hypotheses into perspective with the available data on GLP-1 release in healthy and type 2 diabetic participants, and to address common differences of opinion and some potential misconceptions in the interpretation of commonly quoted landmark publications